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Abstract
Microbiota profiling has the potential to greatly impact on routine clinical diagnostics by detecting DNA derived from live,
fastidious, and dead bacterial cells present within clinical samples. Such results could potentially be used to benefit patients by
influencing antibiotic prescribing practices or to generate new classical-based diagnostic methods, e.g., culture or PCR. However,
technical flaws in 16S rRNA gene next-generation sequencing (NGS) protocols, together with the requirement for access to
bioinformatics, currently hinder the introduction of microbiota analysis into clinical diagnostics. Here, we report on the devel-
opment and evaluation of an Bend-to-end^microbiota profiling platform (MYcrobiota), which combines our previously validated
micelle PCR/NGS (micPCR/NGS) methodology with an easy-to-use, dedicated bioinformatics pipeline. The newly designed
bioinformatics pipeline processes micPCR/NGS data automatically and summarizes the results in interactive, but simple web
reports. In order to explore the utility of MYcrobiota in clinical diagnostics, 47 clinical samples (40 Bdamaged skin^ samples and
7 synovial fluids) were investigated using routine bacterial culture as comparator. MYcrobiota confirmed the presence of
bacterial DNA in 37/37 culture-positive samples and detected bacterial taxa in 2/10 culture-negative samples. Moreover, 36/
38 potentially relevant aerobic bacterial taxa and 3/3 mixtures of anaerobic bacteria were identified using culture and
MYcrobiota, with the sensitivity and specificity being 95%. Interestingly, the majority of the 448 bacterial taxa identified using
MYcrobiota were not identified using culture, which could potentially have an impact on clinical decision-making. Taken
together, the development of MYcrobiota is a promising step towards the introduction of microbiota analysis into clinical
diagnostic laboratories.
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Introduction
The detection, identification, and further characterization of path-
ogenic microorganisms are the major step in establishing appro-
priate (antibiotic) treatment for infectious diseases. However, the
causative microorganism of an infection may not always be de-
tected using current Bgold standard^ culturing techniques.
Further, most molecular-based detection methods, e.g., PCR, re-
quire a priori knowledge of the potential pathogen before a test is
performed. To overcome these limitations, the bacterial compo-
sition can be defined and genera identified using a culture-free,
broad-range PCR strategy that targets the prokaryotic 16S rRNA
gene followed by next-generation sequencing (NGS) [1].
However, to date, 16S rRNA gene NGS methods to profile mi-
crobial compositions have been focused on research questions
mostly, with only a few studies having evaluated the utility of
16S rRNA gene NGS methods for clinical microbiology [2, 3].
Currently, the utilization of 16S rRNA gene NGSmethods with-
in routine clinical diagnostics has been hindered by issues relat-
ing to the generation of PCR artifacts (e.g., chimera formation
and PCR competition) and the susceptibility of 16S rRNA gene
NGS methods to DNA contamination that is derived from the
laboratory environment and/or the reagents/consumables used.
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These limitations hinder the standardization of current 16S rRNA
gene NGS methods to such an extent that non-identical microbi-
ota results may be obtained when repeatedly analyzing the same
sample [4].
Recently, the authors published a micelle PCR/NGS
(micPCR/NGS) methodology that limits the formation of chi-
meric sequences and prevents PCR competition via the clonal
amplification of targeted 16S rRNA gene molecules [5]. In
addition, the micPCR/NGS methodology allows for the utili-
zation of an internal calibrator (IC) to calculate the number of
16S rRNA gene copies for each individual operational taxo-
nomic unit (OTU) present within a (clinical) sample, which
conveniently enables the subtraction of contaminating bacte-
rial DNA via the quantification of 16S rRNA gene copies
within negative extraction control (NEC) samples. The au-
thors showed that the microbiota results obtained using
micPCR/NGS possess a much higher accuracy (precision
and trueness) compared to those obtained using traditional
16S rRNA gene NGS protocols and that the ability to deter-
mine and subtract contaminating 16S rRNA gene copies, re-
sults in contamination-free quantitative microbiota profiles—
with a limit of detection (LOD) of only 25 16S rRNA gene
copies per OTU [6]. This low LOD allows for the detection of
bacterial OTUs at very low abundances or can confirm the
absence of 16S rRNA gene copies in culture-negative results.
Based on these findings, the authors suggested that the
micPCR/NGS protocol could possess distinct advantages
when processing clinical samples for microbiota profiling
compared to traditional (semi-quantitative) 16S rRNA gene
NGS methods that remain vulnerable to false-positive results
(e.g., chimeric sequences or contaminant DNA) and inaccu-
rate measurements of the OTU relative abundances in
polymicrobial clinical samples due to template-specific varia-
tions in PCR efficiencies (i.e., PCR competition). However,
the analysis of 16S rRNA gene NGS data depends on the use
of bioinformatics tools that are complex for non-
bioinformatics educated technicians/clinicians to utilize, and
the required bioinformatics skills are nowadays mostly absent
in clinical diagnostic laboratories.
In this publication, we designed an easy-to-use bioinfor-
matics pipeline to determine bacterial taxa from 16S rRNA
gene sequences that together with the micPCR/NGS strategy
are part of an Bend-to-end^ microbiota profiling platform
(MYcrobiota). The bioinformatics pipeline enables the full
analyses of the NGS data obtained, from raw sequence files
to final web reports that summarize the quantitative microbi-
ota results, without the knowledge of command-line scripts
that would normally be required by 16S rRNA gene NGS
users. As a proof of principle, we explored the utility of
MYcrobiota for use in the clinical diagnostic laboratory by
processing a total of 47 clinical samples and then comparing
the results to conventional Bgold standard^ culture results. The
samples tested included 40 specimens that were obtained from
a variety of damaged skin conditions for which a
polymicrobial biomass was expected, and an additional 7
specimens, obtained from patients who were suspected of
having (prosthetic) joint infections, for which a low bacterial
biomass was expected.
Materials and methods
Ethics statement
An acknowledged national ethics committee from the
Netherlands (Medisch Ethische Toetsingscommissie Noord-
Holland, http://www.metc.nl) approved the study protocol
(M015–021), and all experiments were performed on
leftover material of the included clinical samples in
accordance with the relevant guidelines and regulations. The
national ethics committee waived the need for participant
consent as all data were anonymized and analyzed
retrospectively under code.
Sample collection and study design
This study was performed retrospectively using 47 clinical
samples obtained from 47 subjects. The results obtained by
routine bacterial culturing methods had been used to guide
patient treatment and care. In this study, we re-analyzed these
samples using MYcrobiota and compared the results to the
initial outcome of the culture results. The 47 samples included
in this study were derived from wounds (22), ulcers (10),
abscesses (5), puss (1), erysipelas (1), erythema (1), and 7
synovial fluids obtained from patients with suspected
(prosthetic) joint infections.
Routine bacterial culture
All samples were cultured according to standard laboratory
protocols performed in our laboratory and stored at − 80 °C
for subsequent MYcrobiota analysis. The routine bacterial
culture methods included a 48-h incubation at 35 °C on tryptic
soy agar plates with 5% sheep blood (TSASB, Oxoid), colistin
aztreonam blood agar plates (CAP, Oxoid), and cystine lactose
electrolyte deficient agar plates (CLED, Oxoid) under aerobic
conditions; a 48-h incubation at 35 °C on chocolate agar with
Vitox supplement (CHOCV, Oxoid) under 5% CO2 condi-
tions; and a 48-h incubation at 35 °C on TSASB under anaer-
obic conditions. All Gram-negative rods, beta-hemolytic
streptococci, Staphylococcus aureus, Staphylococcus
lugdunensis, and anaerobic bacteria cultured were reported
as potentially relevant bacteria, of which the identification of
aerobic bacteria was obtained using MALDI-TOF mass spec-
trometry (Bruker). Note that in this study, we did not focus on
optimizing culturing methods to increase the sensitivity of the
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culture results and the routine bacterial culture methods used
may not be 100% efficient for culturing the bacteria that were
detected with MYcrobiota.
Micelle PCR and NGS
DNAwas extracted from all 47 samples using the High Pure
PCRTemplate Preparation Kit (Roche) according to the man-
ufacturer’s instructions. In addition, DNA from the accompa-
nying elution buffer was extracted as a NEC at the same time
in order to allow the subtraction of contaminating bacterial
DNA after NGS processing. The total number of 16S rRNA
gene copies within each DNA extract was measured using a
16S rRNA gene quantitative PCR (qPCR) according to Yang
et al. [7], after which each DNA extract was normalized to
contain either 10,000, or < 1000 16S rRNA gene copies per
microliter. A synthetic microbial community (SMC) sample,
containing 10,000 16S rRNA gene copies of Moraxella
catarrhalis (ATCC 25240), Staphylococcus aureus (ATCC
43300), Haemophilus influenzae (ATCC 10211), and
Clostridium perfringens (ATCC 12915), was processed with
each batch of clinical samples as a positive control (PC) sam-
ple. Prior to amplification bymicPCR, 1000 or 100 16S rRNA
gene copies of Synechococcus DNAwere added respectively
as IC to the normalized DNA extracts containing 10,000 or <
1000 16S rRNA gene copies per microliter. One hundred 16S
rRNA gene copies of SynechococcusDNAwere also added to
the NEC DNA extract. The IC was used to express the
resulting OTUs as a measure of 16S rRNA gene copies by
the use of a correction factor (sample OTU copies = sample
OTU reads × (initial IC copies/IC OTU reads)) as previously
validated elsewhere [6].
16S rRNA gene amplicon library preparation using
micPCR was performed as previously published [6], but we
utilized a different micPCR primer set that made it possible to
replace the former Roche 454 NGS platform with the Illumina
MiniSeq platform. In this study, micPCR amplification was
performed using modified 515F (5′-TCG TCG GCA GCG
TCA GAT GTG TAT AAG AGA CAG TGY CAG CMG
CCG CGG TAA-3′) and 806R (5′-GTC TCG TGG GCT
CGG AGA TGT GTA TAA GAG ACA GGA CTA CNV
GGG TWT CTA AT-3′) primers that amplified the V4 regions
of 16S rRNA genes as recommended for Illumina NGS and
which incorporated universal sequence tails at their 5′ ends to
allow for a two-step amplification strategy. During the second
round of amplification, dual indices and Illumina sequencing
adapters were attached using the Nextera XT Index kit
(Illumina). Paired-end sequencing of the 16S rRNA gene
amplicon library was performed using the MiniSeq system
in combination with the 2 × 150 bp MiniSeq System High-
Output Kit (Illumina), after which FASTQ-formatted se-
quences were extracted from the MiniSeq machine for down-
stream analysis. We utilized the micPCR/NGS approach to
process all samples, including the NEC and the PC, in tripli-
cate in order to increase accuracy and to correct for contami-
nating bacteria DNA derived from the laboratory environment
as previously described [6].
Bioinformatics pipeline
The bioinformatics pipeline designed during this study con-
sists of 23 well-established mothur tools (v.1.36) [8] and an
additional 9 custom-made tools developed by the authors that
have been integrated and combined in Galaxy as a full analy-
sis service to deliver 16S rRNA gene analysis for micPCR/
NGS experiments. Essentially, we have incorporated the func-
tionality of mothur in Galaxy, which is a project dedicated to
simplify the use of complex command-line bioinformatics
tools (such as mothur) using a user-friendly web interface
[9–11], and added new calculator tools to allow for a
completely automatic processing of quantitative micPCR/
NGS data. Importantly, the bioinformatics pipeline presents
the microbiota results together with an extensive overview
of the quality control measurements performed during the
micPCR/NGS data analysis, to the user in an organized fash-
ion via an interactive web report. The complete workflow of
the bioinformatics pipeline is visualized in Fig. 1. All the tools
required for the bioinformatics pipeline can be found in
Galaxy’s Tool Shed (https://toolshed.g2.bx.psu.edu/). A
workflow definition file can be downloaded from GitHub
(ht tps : / /g i thub.com/ErasmusMC-Bioinformat ics /
MYcrobiota) and may be imported to any Galaxy platform,
thereby offering the required set of bioinformatics tools. For
more information on how to install and use this pipeline,
please refer to the documentation in GitHub (https://github.
com/ErasmusMC-Bioinformatics/MYcrobiota).
Quantitative PCR methods
The total bacterial biomass within each DNA extract was
measured using a 16S rRNA gene quantitative PCR
(qPCR) that targets the 16S rRNA gene V5-V7 region,
which is a different region of the 16S rRNA gene com-
pared to MYcrobiota [7]. Therefore, the 16S rRNA gene
qPCR is a complementary technique that enables the val-
idation of the MYcrobiota process when determining the
total number of 16S rRNA gene copies. For this, CT
values were related to a serial dilution of the previous
calibrated and normalized SMC sample that contained
mixed and equimolar concentrations of four bacterial spe-
cies and ranged from a total of 100 to 10,000 16S rRNA
gene copies per PCR. In addition, the S. aureus-specific
biomass was assessed within each DNA extract using a S.
aureus qPCR that employs a S. aureus-specific marker as
described by Martineau et al. [12]. Here, CT values were
related to a serial dilution of only the calibrated S. aureus
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(ATCC 43300) DNA stock that ranged from a total of 10
to 10,000 copy numbers of the Martineau fragment. The
PCRs were performed in 10-μL reaction volumes using
the LightCycler 480 Probes Master (Roche) with the ad-
dition of 0.5 and 1.0 μM of each PCR primer for the 16S
rRNA gene and S. aureus qPCRs respectively. Also,
0.25 μM of a Fam-labeled probe was added for the real-
time detection of the 16S rRNA gene amplification, and
1× Resolight Dye (Roche) was added to the S. aureus
qPCR in order to measure the S . aureus DNA
amplification. All PCRs were performed using the follow-
ing conditions: initial denaturation at 95 °C for 5 min
followed by 45 cycles of PCR, with cycling conditions
of 5 s at 95 °C, 10 s at 55 °C, and 30 s at 72 °C.
Availability of data and materials The datasets generated and
analyzed during the current study are available in the
Sequence Read Archive repository with accession number
SRP109023, https://www.ncbi.nlm.nih.gov/sra/?term=
SRP109023.
• Read-pair merging: combines forward and reverse reads into contigs
• Subsample large datasets: creates a smaller subset from the original set
• Quality control: removes primer sequences, short reads and ambiguous reads
• Simplify datasets: removes duplicate reads
• Alignment: aligns reads to a customized reference alignment
• Chimera removal: removes potentially chimeric sequences
• Classify sequences: assigns reads to a reference taxonomy outline
• Remove non-prokaryotic DNA: removes reads classified as non-prokaryotes
• OTU clustering: clusters reads into OTUs at 97% similarity
• IC normalization: converts reads to 16S rRNA gene copies using the IC
• Averaging triplicates: averages results over multiple technical replicates
• NEC correction: corrects for contaminating bacterial DNA using the NEC
Calculator       Example_R1 Step                                                       Example_R1
Number of reads removed at each filtering step :
Download removed reads at each filtering step here
OTU           16S rRNA gene copies   Kingdom    Phylum               Class                              Order                Family                         Genus                         BLAST
Output  (iReport)
FASTQ processing stepsInput
Taxonomy Diversity Quality Control
Clinical Sample 1
Clinical Sample N
Positive Control (PC)
Negative Extraction Control (NEC)
Fig. 1 Schematical overview of the bioinformatics pipeline. FASTQ-
formatted sequences obtained from triplicate experiments using
micPCR/NGS (R1, R2, and R3) are automatically processed via the use
of 32 (mothur) tools that have been integrated and combined in Galaxy as
an Bend-to-end^ analysis service. The results obtained per sample
(average of triplicate results) are presented to the user in a single,
interactive iReport that consist of three tabs. The taxonomy tab
visualizes and lists the resultant microbiota profiles. The diversity tab
summarizes the results of three diversity calculators (Chao1, Shannon,
and Simpson). The quality control tab provides an extensive overview of
the quality control measurements during the analysis
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Results
Development of an easy-to-use bioinformatics
pipeline
In order to analyze 16S rRNA gene NGS data obtained using
micPCR/NGS, we designed a Galaxy-based bioinformatics
pipeline for use in clinical diagnostics. This workflow is large-
ly based on the well-established standard operating procedure
(SOP) defined by the creators of mothur [13]. We have
adapted the SOP to our specific use-case by integrating sev-
eral custom-made tools that allow for the subsampling of large
datasets, the averaging over multiple technical replicates,
converting the number of obtained sequence reads per OTU
to 16S rRNA gene copies per OTU via the use of an IC, and
correction for contaminating bacterial DNA via the use of
NECs. All results are presented to the user as a single, inter-
active web report in Galaxy using the iReport tool [14]. The
iReport was designed to visualize the resultant microbiota
profiles using KRONA [15], list quantitative microbiota pro-
files in OTU tables (with the microbial load per OTU reported
as 16S rRNA gene copies), summarize results of diversity
calculators, and provide an extensive overview of the quality
control measurements during the analysis. Importantly, the
iReport is relatively small in size (~ 6 MB per sample for
our datasets) that enables easy sharing and storage of 16S
rRNA gene NGS results (Fig. 1).
Validation of the MYcrobiota process
As shown in Fig. 2, MYcrobiota results obtained from the PC
that was profiled in three independent experiments showed a
median value of only a 1.3-fold (± 0.2) difference between the
measured 16S rRNA gene copies per bacterial species and the
expected 10,000 16S rRNA gene copies per bacterial species
present in the PC. In addition, comparisons between the mea-
sured 16S rRNA gene copies determined in actual clinical sam-
ples using MYcrobiota compared to qPCR results revealed an
average of only a 1.5-fold (± 0.5) and a 1.3-fold (± 0.4) difference
for the total bacterial biomass and the Staphylococcus OTU-
specific biomass respectively. Of note, 10 of the 47 clinical sam-
ples included in this study resulted in culture-negative results,
and the absence of bacterial DNA in these samples was con-
firmed with both qPCR and MYcrobiota methods. Also, one
discrepant sample was detected that showed a 20-fold higher
abundance of staphylococci detected by MYcrobiota compared
to that detected by qPCR. This result can be explained by the
presence of S. aureus and S. non-aureus within this sample. In
fact, the S. aureus qPCR showed a 100% specificity compared to
S. aureus culture-positive results and indicates the presence of S.
non-aureus bacteria within 7 additional samples in which the
Staphylococcus OTU was detected using MYcrobiota but no S.
aureus could be cultured. Taken together, these data demonstrate
the accuracy of the MYcrobiota process and the ability to incor-
porate quantitative results obtained from additional (species-
specific) qPCRs.
Comparing MYcrobiota results to routine bacterial
culture
In order to explore the utility of MYcrobiota in the field of
clinical diagnostics, we processed a total of 47 clinical samples
and compared the results to routine bacterial culture. All bacterial
genera detected using culture and MYcrobiota are reported per
sample in Table 1. Using standard bacterial culture techniques,
our laboratory detected a total of 38 potentially relevant aerobic
Fig. 2 Accuracy of 16S rRNA gene copy determination using
MYcrobiota. The expected number of 16S rRNA gene copies within
the positive control (PC) was compared to the measured number of 16S
rRNA gene copies using MYcrobiota (green dots). The PC contained
10,000 16S rRNA gene copies of four different bacterial species and
was processed in three independent MYcrobiota experiments. The
indirect estimation of the total bacterial biomass within 37 clinical
samples using MYcrobiota was compared to the total 16S rRNA gene
copies measured directly using a 16S rRNA gene qPCR (blue dots). The
StaphylococcusOTU-specific biomass from 13 S. aureus culture-positive
samples was compared to the S. aureus biomass detected directly using a
S. aureus-specific qPCR (yellow dots). In order to compare the number of
S. aureus genome copies estimated using qPCR to the number of 16S
rRNA gene copies detected using MYcrobiota, the estimated S. aureus
genome copies were first multiplied by a factor of 6 to correct for
differences in copy numbers of the Martineau fragment and the 16S
rRNA gene present on the S. aureus genome. The calculated differences
between methods were plotted using a binary logarithmic scale
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Table 1 Bacterial genera identified from 47 clinical samples using routine bacterial culture and MYcrobiota
Sample Routine bacterial culture MYcrobiota
01_U Commensal flora (1+) Anaerobic bacteria (346,300), Corynebacterium (10,725)
02_U Commensal flora (2+) Staphylococcus (941)
03_W Commensal flora (1+) Anaerobic bacteria (263), Streptococcus (33), Staphylococcus (25)
04_U Pseudomonas (3+), Staphylococcus (2+)
Pseudomonas (4,706), Staphylococcus (848), Enterococcus (135), 
Anaerobic bacteria (102)
05_U
Proteus (2+), Enterobacteriaceae* (2+), 
Streptococcus (1+), Commensal flora (1+)
Anaerobic bacteria (8,271), Proteus (3,510), Streptococcus (632), 
Enterobacteriaceae* (333)
06_U Commensal flora (1+) Moraxella (8,947), Corynebacterium (734)
07_W Enterobacteriaceae (1+) Enterobacteriaceae* (5,386), Bacillus (44)
08_W Negative Negative
09_W Commensal flora (1+) Anaerobic bacteria (523), Staphylococcus (31)
10_A
Anaerobic bacteria (2+), Pasteurella (2+), 
Streptococcus (2+)
Anaerobic bacteria (3,704,750), Pasteurella (242,250), Streptococcus
(28,625)
11_W Enterobacteriaceae* (3+), Staphylococcus (3+)
Enterobacteriaceae* (3,420,786), Acinetobacter (1,126,632), 
Staphylococcus (32,760)
12_A Enterobacteriaceae* (2+), Streptococcus (2+)
Enterobacteriaceae* (18,046), Streptococcus (6,409), Enterococcus
(67)
13_Es Commensal flora (1+)
Staphylococcus (344), Anaerobic bacteria (150), Dermabacteraceae* 
(93), Haemophilus (64), Corynebacterium (53)
14_W Commensal flora (1+) Staphylococcus (31)
15_U Staphylococcus (4+) Staphylococcus (17,035)
16_U
Enterobacteriaceae* (3+), Stenotrophomonas 
(2+), Commensal flora (2+), Proteus (1+), 
Pseudomonas (1+)
Enterobacteriaceae* (828,310), Proteus (250,670), Stenotrophomonas
(11,760)
17_W Staphylococcus (1+), Commensal flora (1+) Staphylococcus (4,886)
18_W Staphylococcus (3+), Commensal flora (2+) Staphylococcus (141,120), Corynebacterium (4,959)
19_W Streptococcus (2+), Staphylococcus (1+)
Streptococcus (114,257), Staphylococcus (44,772), Corynebacterium
(8,749), Anaerobic bacteria (897)
20_W Enterobacteriaceae* (3+), Staphylococcus (2+) Enterobacteriaceae* (4,574,310) 
21_U Commensal flora (2+)
Moraxella (1,066,608), Acinetobacter (142,155), Pseudomonas
(30,051), Anaerobic bacteria (30,051), Corynebacterium (23,976), 
Alkanindiges (2,187)
22_W Staphylococcus (2+), Commensal flora (1+) Staphylococcus (105,648)
23_Et Staphylococcus (2+), Commensal flora (2+) Staphylococcus (14,803), Corynebacterium (66)
24_U
Staphylococcus (3+), Streptococcus (3+), 
Commensal flora (2+)
Staphylococcus (231,756), Anaerobic bacteria (96,740), 
Streptococcus (15,904), Enterococcus (1,680)
25_W Staphylococcus (3+), Commensal flora (2+)
Staphylococcus (23,175), Corynebacterium (15,488), Anaerobic 
bacteria (1,271)
26_W Commensal flora (1+)
Staphylococcus (4,142), Anaerobic bacteria (101), Corynebacterium
(94), Streptococcus (47)
27_A Streptococcus (1+)
Anaerobic bacteria (1,062,060), Streptococcus (5,490), Treponema 
(3,435), Gemella (1,425), Mycoplasma (870), Tannerella (720)
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bacterial genera within 25 clinical samples and obtained a posi-
tive culture of a mixture of anaerobic bacteria in 3 samples. No
bacteria were cultured from 10 samples, and an additional 10
samples resulted in the growth of bacteria that were all presumed
to be commensal flora. In contrast, usingMYcrobiota, we detect-
ed a total of 448 bacterial operational taxonomic units (OTUs) in
39 samples of which 337 OTUs (75%) could be identified as
anaerobic bacterial genera that were detected in 21 samples. No
bacterial DNA was measured in 8 out of 10 culture-negative
samples. The sensitivity for bacterial culture detection by
MYcrobiota was determined at 100% and the specificity at
83% using culture as Bgold standard.^
The majority of bacterial genera identified with culture were
also identified using MYcrobiota. As shown in Table 2,
MYcrobiota detected 36 of all 38 aerobic bacteria cultured on a
genus-level taxonomy and confirmed the growth for anaerobic
bacteria in 3 samples (sensitivity 95%; specificity 95%).
Important to note, the two discrepant bacterial genera were mea-
sured using themicPCR/NGS strategy, but below the technique’s
LOD of 25 16S rRNA gene copies per OTU. In contrast, the vast
majority of bacterial genera identified with MYcrobiota were
presumed to belong to the commensal flora using culture or were
not cultured at all (Table 1). These additional taxa include poten-
tial pathogens such as theKingellaOTU that was detected from a
28_W Commensal flora (2+), Streptococcus (2+) Anaerobic bacteria (114,004), Streptococcus (43,208)
29_A Streptococcus (1+)
Streptococcus (12,225), Anaerobic bacteria (3,384), Gemella (299), 
Enterococcus (295), Haemophilus (221), Capnocytophaga (156), 
Granulicatella (122), Neisseria (119), Rothia (52), Lautropia (35)
30_W Negative Negative
31_U
Acinetobacter (2+), Enterobacteriaceae* (2+), 
Commensal flora (2+)
Acinetobacter (518,396), Stenotrophomonas (423,320), 
Enterobacteriaceae* (12,046), Corynebacterium (5,928), Bordetella
(4,636), Brevibacterium (988)
32_W Staphylococcus (2+), Commensal flora (1+)
Anaerobic bacteria (251,692), Streptococcus (30,408),
Staphylococcus (8,960)
33_W Staphylococcus (1+), Commensal flora (1+)
Staphylococcus (466), Anaerobic bacteria (171), Streptococcus
(105), Acinetobacter (84), Corynebacterium (41)
34_W Staphylococcus (3+) Staphylococcus (218,141)
35_W Commensal flora (2+) Staphylococcus (5,121), Anaerobic bacteria (769), Roseomonas (40)
36_W Anaerobic bacteria (3+), Commensal flora (1+) Anaerobic bacteria (493,183), Streptococcus (1,045)
37_W Streptococcus (2+) Streptococcus (11,457)
38_W Anaerobic bacteria (3+) Anaerobic bacteria (830,531)
39_P Streptococcus (2+) Streptococcus (10,277,376)
40_A Negative
Anaerobic bacteria (94,633), Enterobacteriaceae* (2,944),
Streptococcus (44), Thalassospira (36)
41_S Negative Negative
42_S Negative Negative
43_S Negative Negative
44_S Negative Negative
45_S Negative Negative
46_S Negative Negative
47_S Negative Kingella (25)
Samples were derived from wounds (W), ulcers (U), abscesses (A), puss (P), erysipelas (Es), erythema (Et), and suspected joint infections (S). Cultured
bacteria other than Gram-negative rods, beta-hemolytic streptococci, S. aureus, S. lugdunensis, and anaerobic bacteria were reported as commensal flora.
The semi-quantitative culture results are presented as 1+, 2+, 3+, or 4+, depending on which quadrants demonstrate bacterial growth. The presence of
anaerobic bacteria was reported as either a positive or a negative result. Bacterial species and OTUs detected using culture and MYcrobiota respectively
are grouped at the genus level to compare results. Red shades indicate bacterial genera that were only identified by culture and blue shades indicate
bacterial genera that were only identified byMYcrobiota (with Bcommensal flora^ culture results representing a positive detection signal for any kind of
aerobic bacterial OTU identified by MYcrobiota). The number of 16S rRNA genes measured using MYcrobiota is indicated in parentheses
*Several bacterial genera that belong to the Enterobacteriaceae and Dermabacteraceae families could not be differentiated at a 97% similarity level
using MYcrobiota
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synovial fluid sample obtained from a juvenile patient that was
not detected using culture and was confirmed using a Kingella
kingae-specific PCR.
Discussion
In this study, we developed and explored the utility of an Bend-to-
end^microbiota profiling platform (MYcrobiota)—consisting of
our previously published 16S rRNA gene sequencing methodol-
ogy (micPCR/NGS) in combination with an easy-to-use bioin-
formatics pipeline—to investigate human samples for the clinical
diagnostic laboratories. The bioinformatics pipeline designed
during this study allows for a fully automated sequence interpre-
tation of 16S rRNA gene NGS data that is obtained using the
validated micPCR/NGS protocol without the need for advanced
bioinformatics skills that are often unavailable in the clinical
diagnostic laboratories. The MYcrobiota results are presented
using (interactive) visualizations and tables, including an over-
view of all removed sequences during the analysis that allows for
a manual evaluation of the quality measurements pre-installed
within the bioinformatics pipeline. Moreover, connections of
OTU representative sequences to the external NCBI database
are available and can be used to ensure that the taxonomic iden-
tification of bacterial genera is correct [16]. Importantly, the sum-
marizing reports are relatively small in size, and storage of these
files enables the traceability of patient test results that are required
for clinical diagnostic laboratories according to quality
requirements.
Using MYcrobiota, we processed a total of 47 clinical sam-
ples and compared the results to routine bacterial culture. Our
results showed that themajority of bacteria identifiedwith culture
were also identified with MYcrobiota, but the majority of bacte-
rial taxa identified with MYcrobiota were not identified using
culture. Many of the additional bacterial taxa identified using
MYcrobiota are obligate anaerobes that were commonly detected
as a large component of the microbial population in samples
obtained from damaged skin sites, which is consistent with pre-
vious studies [17, 18]. Indeed, it is well known that anaerobic
bacteria are able to cause serious and life-threatening infections
but are often overlooked due to their requirement for appropriate
methods of collection, transportation, and cultivation [19].
Therefore, the culture-free MYcrobiota detection platform can
play an important role in the identification of the bacteriological
etiology of anaerobic infections or any other infections caused by
fastidious microorganisms. Of note, it could be argued that the
development of extensive culture techniques (so-called
culturomics) may eventually facilitate the successful culture of
supposedly Bnon-culturable^ microbial isolates [20].
In addition to the accurate detection and identification of bac-
terial OTUs within clinical samples, MYcrobiota also provides
the relative abundances in combination with the absolute abun-
dances for each detected bacterial OTU. This feature allows cli-
nicians to obtain a comprehensive overview of the microbial
composition of the clinical sample so that each quantified bacte-
rial OTU, as well as the bacterial community as a whole, might
be taken into account in clinical decision-making. Additionally,
MYcrobiota allows for the removal of contaminating DNA from
environmental sources in order to accurately and reliably inves-
tigate very low bacterial biomass, or no bacterial biomass, clini-
cal samples [6]. For example, MYcrobiota confirmed the ab-
sence of 16S rRNA gene copies in eight of the ten samples that
generated culture-negative results. The two discrepant samples
contained either anaerobic bacteria or low amounts of the
Table 2 Comparison of the cultured bacterial taxa to MYcrobiota results
Bacterial taxa Number of positive samples Sensitivity (%) Specificity (%)
Routine bacterial culture MYcrobiota
Acinetobacter 1 4 100 98
Enterobacteriaceae* 7 8 100 98
Pasteurella 1 1 100 100
Proteus 2 2 100 100
Pseudomonas 2 2 67 100
Staphylococcus 14 20 93 100
Stenotrophomonas 1 2 100 100
Streptococcus 10 16 100 97
Anaerobic bacteria 3 21 100 71
Total 41 76 95 95
The culture results are restricted to genus-level classifications in order to compare the OTUs detected using MYcrobiota to the culture-based results. The
presence of anaerobic bacteria was reported as either a positive or a negative result. BCommensal flora^ culture results were interpreted as a positive
detection signal for any kind of aerobic bacterial OTU identified by MYcrobiota to perform specificity calculations
*Several bacterial genera that belong to the Enterobacteriaceae family could not be differentiated at a 97% similarity level using MYcrobiota
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fastidiousKingella bacterium respectively. The ability to confirm
culture-negative results improves the reliability of culture-
negative diagnostic results. Additionally, the ability of
MYcrobiota to detect bacterial OTUs at very low abundances
makes MYcrobiota a suitable method to investigate normally
sterile body sites, such as synovial fluids, cerebrospinal fluids,
and blood samples. It should be noted however that the authors
are aware of the fact that the construction ofMYcrobiota is only a
first step in the transition of microbiota research into actual clin-
ical diagnostics. Extensive clinical and financial validation stud-
ies will be needed in order to validate and justify the routine
introduction of molecular microbiota profiling methods into clin-
ical diagnostic laboratories.
In conclusion, the stepwise development of MYcrobiota
paves the way to introduce quantitative microbiota profiling into
the clinical diagnostic laboratory. The method provides a highly
accurate and comprehensive overview of the microbial compo-
sition of clinical samples or, alternatively, confirms the absence
of 16S rRNA gene copies in culture-negative samples, using a
standardized and validated 16S rRNA gene NGS workflow.
Despite some shortcomings, e.g., lack of species identification
and the inability to provide detailed information on antibiotic
susceptibility, our data illustrates that MYcrobiota has promising
applications in the field of clinical diagnostics and warrants in-
vestment in future studies to accurately evaluate the clinical rel-
evance of 16S rRNA gene NGS results in clinical samples.
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